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Abstract

The oxidoreductase enzymes that comprise the human liver cytochrome P450 (CYP450)
system are vital in metabolism, lipid synthesis, and detoxification of the human body. It
is known that enzymes in this pathway process the majority of pharmaceuticals, thus the
study of these enzymes proves to be valuable in determining potentially harmful drug
interactions. The amazon acaí berry has gained popularity in recent years due to its
reported health benefits and has been deemed by many health organizations as a
superfood. The purpose of this research was to determine the effects of isolated acaí berry
extracts on the activity of the CYP 450 enzyme 3A4 and 2D6 to determine if there is a
possible drug interaction. The results obtained suggest that compounds in certain acaí
fractionations, specifically 94-C (Diosmetin) inhibit the enzymes’ activity by
approximately 68%. While further research into the metabolism of acaí berries must be
conducted, these results imply that eating acaí berries may be harmful while taking
certain medications due to the inability of CYP 3A4 and 2D6 enzymes to adequately
metabolize the drug.
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Inhibition of Human Cytochrome P450-3A4 isoform by Crude Extracts from Acai
Berry
The Liver is one of the most important organs in vertebrates. It is located
in the upper right quadrant of the abdomen, below the diaphragm. The liver has a
wide variety of functions such as detoxification of various metabolites, protein
synthesis, and biochemical secretion. In addition, the liver’s unique role is that it
is responsible for eliminating foreign compounds (xenobiotics) like drugs and
toxins from the body by specific types of metabolism that involve using
cytochrome P450 enzymes, which are a family of isozymes responsible for the
biotransformation of several drugs (1). The synthetic role of the liver will be
disregarded and the detoxification role of the liver will be focused on due to the
importance of this research on the human body and the danger that a natural
product can produce.
It is well known that the inhibition or activation of human liver
cytochrome P450 enzymes by compounds of natural product origin can result in
adverse drug interactions(19). By inhibiting one or all of the P450 isoforms, the
Brazilian Acai berry has gained considerable popularity due to its health benefits.
It can suppress inflammation in individuals with cancer and arthritis. It improves
digestion along with sexual performance and general health (12). Acai products
range from the raw freeze-dried powder, supplement tablets, beverages such as
juice, wine, smoothies or energy drinks, and even food products such as jelly or
ice cream (19).
Human liver cytochrome P450 consists of six different isozymes that play
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important roles in drug metabolism. CYP1A2, CYP2C19, CYP2C9, CYP2D6,
CYP2E1, and CYP3A4 (17, 21). The idea that these isoforms could be affected by
Acai berry came from a classic example of Grapefruit Juice and the plant
St.John’s Wart (4). Grapefruit Juice was found to have the furanocoumarins
compound that is responsible for inhibiting the CYP3A4 in two ways, if
furanocoumarins inhibits the hepatic CYP3A4, it will affect the medication
metabolism (10, 13). On the other hand, if it inhibits the enterocyte CYP3A4, the
medication absorption in the intestine would be affected (5). Likewise, Black
cohosh extracts was found to have a herbal drug interactions that inhibit the 3A4
and 2D6 human isoforms (22). Human P4501A2, P4503A4, and P4502C9
isoforms metabolize anticoagulant drugs such as warfarin and clopidogrel that are
susceptible to pharmacokinetic-related drug interactions with natural products (8).
Clopidogrel – if used in wrong dosages- would affect the formation of platelets
and cause internal bleeding (2). Whereas warfarin interacts with nonsteroidal antiinflammatory drugs and causes a serious bleeding complications (7).
The amazon acaí berry has gained popularity in recent years due to its
reported health benefits and has been deemed by many health organizations as a
superfood. In this research, different extracts from the Brazilian acai berry were
examined for their potential to inhibit human liver cytochrome P450 enzymes to
determine the effects of isolated acaí berry extracts on the activity of the CYP 450
enzymes 3A4 to determine if there was the potential for adverse drug interaction.
The isoform 3A4 was explored with the goal of identifying potential drug-extract
interactions or identifying specific P450 interactions with potential health benefits
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(1, 24). To establish this, the activity of the enzyme was measured using a
commercial assay kit in the presence and absence various acai fractions. The
results obtained suggest that compounds in certain acaí fractionations inhibit the
activity of the human 3A4 up to 70%. Furthermore, by using an activity-guided
fractionation approach it was determined that one of the primary compounds in
acai berries that is responsible for this inhibition is diosmetin, which is a known
flavonoid inhibitor of CYP 450 enzymes. The 3A4 isoform in particular is
significance with respect to drug interactions involving anticoagulant
medications. P4503A4 was affected critically by St. John’s wort (A herbaceous
plant) (16). This plant is a source of hyperforin, an active ingredient that has a
strong affinity for the pregnane xenobiotic receptor (PXR), as a PXR ligand,
hyperforin promotes expression of CYP3A4 enzymes in the small intestine and
liver. This in turn causes induction of CYP3A4 and can reduce the oral
bioavailability of many drugs making them less effective (14, 23). Furthermore,
goldenseal was found to be inhibitory to 3A4.
7-Benzyloxy quinoline, 7-benzyloxy-trifluoromethylcoumarin,
testosterone are the main substrates that is responsible of inhibiting P4503A4,
These substrate can bind to different domains at the active site of CYP3A4 and
that any pair can interact with each other in a manner that is distinct from simple
competitive inhibition. Researches have shown that BQ and BFC show a larger
inhibition when interacting with a natural product like the ones discussed earlier.
This is emphasized by highlighting the investigation and prediction of CYP3A4ligand interactions. This research would also give knowledge about enzyme
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substrate binding properties as it may play a major key to the understanding of
cytochrome P450 inhibition patterns from herbs and drugs (3, 15).
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Materials and Methods

Acai berry freeze dried extract was purchased from optimally organic Inc.
The identity of the dried powder was identified by submitting it for genetic
analysis, which ultimately showed that it is closely related to the authentic acai
berry sample.
Fractionation of the Acai Powder
455g of freeze dried acai powder was extracted in 4L MeOH to generate
methanol extract. The volume was reduced to 2L by filtering the methanol
fraction. The solution consisted of 9:1:10 ratio of MeOH:H2O:Hexane in a total
volume of 4L. Since the aqueous MeOH is immiscible with hexane, 19.3g of
hexane fraction would generate by defatting the original MeOH. The aqueous
MeOH fraction was dried and partitioned with 4:1:5 chloroform:MeOH:H2O in a
total of 4L. Finally, the chloroform layer produced 7.2g chloroform and the
remaining aqueous solution resulted 6.5g butanol and 16.8g aqueous fractions.
P4503A4
10 mM NADP+ stock solution: 382 mg NADP+ in 50 ml Milli-Q water.
Store at 4 °C. 100 mM glucose-6-phosphate: 3.4 g in 100 ml Milli-Q water. Store
at 4 °C. 103 IU/ml yeast glucose-6-phosphate dehydrogenase: 1.0 mg in 1 ml 10
mM Tris-acetate buffer (pH 7.4), containing 20% glycerol (v/v) and 1.0 mM
EDTA. Store at 4°C. 4 mM BFC stock solution: 2.56 mg in 2 ml methanol. Stored
in Teflon-sealed amber glass vial at 4 °C. 1 mM ketoconazole stock solution: 5.31
mg in 10 ml methanol. Stored in Teflon-sealed glass vial at 4°C. NADPHgenerating system: combine 50 parts 10 mM NADP+, 100 parts 100 mM glucose-
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6-phosphate and 1 part 1 mg/ml yeast glucose 6-phosphate dehydrogenase.
Prepare fresh daily and store on ice when not in use. Stop buffer: 80% acetonitrile
and 20% 0.5 M Tris-base (v/v), stored at ambient temperature. P450-BFC 2× mix:
mix P450 3A4 bicistronic membranes and 4 mM BFC stock solution in 100 mM
potassium phosphate buffer (pH 7.4) so that the final concentration of P450 is 20
nM and BFC is 40 μM. Prepare the mix fresh daily and keep on ice. Dispense 60
μl 100 mM potassium phosphate buffer into the wells (column 2–12) in a 96-well
microplate using a multichannel pipette. Dispense 118 μl 100 mM potassium
phosphate and 2 μl of 1 mM ketoconazole into the wells (column 1). Serially
dilute 60 μl inhibitor solution from the wells in column 1 to the other wells (2-10).
Discard the extra 60 μl solution in the wells in column 10. Dispense 100 μl P450BFC 2× mix in all the wells. Add 75 μl stop buffer to the wells in
column11.Preincubate the plate at 37 °C for 5 minutes.Add 40 μl NADPH
generating system into each well to initiate the reaction. Incubate the plate at 37
°C for 20 minutes. Stop the reaction by adding 75 μl stop buffer to each well
(except wells in column 11) (6, 18).
Methodological summary of the fractionation approach that was used in
this research can be followed by the following: A luminescent commercial
enzyme assay (Promega P450-Glo Assay) was performed in the presence of
various acaí berry extracts. The reaction was started using 0.2 mM NADPH and
stopped using lucifierin detection reagent. The generated luminescent product was
quantified using a Tecan M200 Pro Infinite plate reader. The assay conditions and
preparation of samples were in accordance with the
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recommended Promega protocol. The percent activity of each experimental
sample was determined and was used to determine the relative amount of
inhibition caused by each fraction. An identical assay was preformed using
various concentrations of Diosmetin (94-C) to obtain a dose response curve. The
results were obtained and analyzed through Microsoft excel.
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Results and Discussion

Figure 1. Freeze Dried Acaí Berry
fractionation Scheme. Amazon dried
Acai berry was fractionated into multiple
series. The 34 series represents the most
crude extracts. The scheme was followed
to determine the effective dose response
of the flavonoids that was found to be 94H based on the percent activity of each
fraction. The higher that activity, the less
the inhibition, so fractions that showed
lower activity were further fractionated
and tested.
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Table 1. % Activity 3A4-34 Series fractions

Fraction

Luminescence

Positive

Percent of +

7746.5

100

34-7

1086.667

14

34-8

768

10

1973.5
3378.25

25
100

34-1

618

18

34-2

1083

32

34-6

984.125

29

34-10

558.125

17

34-9
Positive

Positive

5729.5

100

34-3

1339

23

34-4

2532.25

44

34-5

1545.25

27

Figure 2. 34 Series inhibition of
CYP 3A4. The percent activity of
each sample was determined by
comparing the luminescent values of
each experimental sample to the
luminescence of the positive control.
The fractions were added at a
concentration of 25 mg/mL. While
many fraction showed strong
inhibition, 34-8 proved to be the
strongest inhibitor with a percent
activity of 10%.
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Table 2. % Activity 3A4-38 Series fractions

Fraction
Positive

Percent of +
100

38-1

37

38-2

27

38-3

30

38-4

26

38-5

28
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Figure 3. 38 Series inhibition of CYP3A4. The final concentration of
fraction in each sample was 25 mg/mL. While all fractions evidenced a
similar level of inhibition, all with a percent activity 30-40%, it was
determined that subsequent fractionations from 38-3 would be tested due to
their relative availability.

Table 3. % Activity of 3A4-62 Series.
Fraction Luminescence Percent of +
Positive
5346
100
62-1
3972.75
74
62-2
2029
38
Positive
7309
100
62-3
2501
34
62-5
2447.5
33
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Figure 4. Percent inhibition of
3A4-62 series. The activity of the
fractions of the 62 series was
compared with a positive control.
The lumenescence activity of
50uL/mg of each fraction were
used in order to determine the
inhibition percentage of each
fraction. Results shows that 62-1
had the highest inhibition of ~80%
while 62-2, 62-3, and 62-4 had the
Table
% Activityofof~38%
3A4-63 series
same4.inhibition
Fraction Luminesence Percent of +
Positive
21704
100
4
6966
32
5
8479.5
39
6
6186
29
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Figure 5. 63 Series inhibition of
CYP3A4. The luminescence assays
preformed with the 63 series had a
reduced fraction concentration of 5
mg/mL, due to the increased purity
of these samples. It was determined
that fractionations from 63-4 would
be further analyzed due to its
significant level of inhibition,
Table
5. % Activity
of 3A4-98
Series.
evidenced
by its 38%
activity.
Fraction

Luminescence

percent of +

Positive

821

100

A

659

80

B

524

64

3705.5

100

C

1429

39

D

1253

34

E

1308

35

Positive

1759

100

H

448

27

I

776

44

Positive
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Figure 6. 94 Series inhibition of
CYP3A4. The assays carried out
using the 94 series had a final
fraction concentration of 5 mg/ml.
The fractions that provided the
strongest inhibition were 94-C
(Diosmetin), 39% activity and 94Table
6. % provided
activity of27%
fouractivity.
different dilutions of diosmetin.
H which
Dilutions

precent of +

Positive

100
25

23.75596616

1

63.71390766

0.5

62.26312556

0.2

71.72156325
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A

B

Figure 7. Percent inhibition of
four different dilutions of
diosmetin. A) The luminescent
assay previously performed with
various fractions of acaí berry was
repeated using various
concentrations (0.2mM-25mM) of
purified diosmetin. Bar graph
shows an increase enzyme
inhibition when decreasing
concentration. B) The results
suggest that the effective inhibitory
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The results of this experiment strongly suggest that compounds in acaí
berries inhibit CYP 3A4 in vitro. The results from the most crude chloroform
extracts tested, 34 series, suggest that the majority of these fractions significantly
inhibit CYP3A4 (Figure 1). These results were obtained by comparing the
luminescence activity of each fraction to the value of the positive control.
Reactions were carried in a 25µg/ml molar concentration. Concentrations were
determined based on the purity of the sample factions which differ depending on
the fractionation method and the place where they have originated from. Most
notably, 34-8 proved to be the strongest inhibitor of CYP3A4, which is evidenced
by 3A4’s low percent activity of 10% in the presence of this fraction. A low
percent activity means that there is large percent inhibition of the enzyme in the
fraction.
Upon continuation of the activity guided fractionation approach, it was
discovered that fractions in the 38 series all inhibit 3A4 to a similar level (30-40%
activity); however, fractions from 38-3 were further pursued due to its relative
availability (Figure 2). Table 2 shows the values of the luminescence activity of
the 38 series fractions. Percentages are relatively close (26%-37%).
The activity guided fractionation approach was further performed on the
63 series. The assay results from the 63 series indicated that both 63-6 and 63-4
were inhibitors of CYP 3A4, both yielding a percent activity around 40% (Figure
3). Reactions were carried on a 5µg/ml plate reader wells. This reduction in
concentration is due to the purity of the fractions. Due to its significant inhibition,
fractionations from 63-4, 94 series, were tested. Potency of diosmeting on
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CYP3A4 was determined using the same fractionation approach, it was
discovered that 94-C and 94-H were the most potent inhibitors with a percent
activity of 39% and 27%, respectively.
The identity of 94-C was previously determined to be the flavonoid
compound Diosmetin, also known as 5,7,3'-trihydroxy-4'-methoxyflavone, which
is a known inhibitor of CYP enzymes (2). Diosmetin is an O-mythelated flavone
that was found to waken tyrosine kinase enzyme. In addition, it was found to play
a role pharmacologically by being anti cansourous, antioxidant, antiinflammatory, and also, antimicrobial. In order to determine the effective
inhibitory dose of Diosmetin on 3A4, a dose response curve was produced (Figure
6) (11). It was determined that the effective inhibitory dose of Diosmetin is
between 1-5mM, which is evidenced by the large decrease in enzyme activity
between these two concentrations (Figure 6b).
The quantity of acaí berries that must be consumed to reach this inhibitory dose of
Diosmetin is unknown, as the concentration of this compound in crude acaí berry
has not yet been determined. It was also found that fractions 34-1 and 94-H
strongly inhibit 3A4. The identity of these fractions is currently being determined
by an outside source.
The cytochrome p450 family has a liege group of enzyme that is found
predominantly in the liver. This group of enzymes is responsible for various
functions, the most primary functions being metabolism of both nutrients and
exogenic components such as pharmaceuticals. It is known that cytochrome p4503A4 is larger responsible for metabolizing pharmaceuticals. It has been
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approximated that this enzyme is responsible for metabolizing 30% of
pharmaceuticals that are currently on the market. Further studies have shown that
this enzyme is inhibited by certain components of grapefruit. Thus, inhibition of
this enzyme while taking certain drugs, such as statins, has been shown to be
harmful due to the inability of drug clearance; as a result, toxic levels of drugs
build up in the system resulting in prolonged defects of these drugs and magnified
effects of these drugs, both of which lead to undesirable outcome.
Similar studies are currently being explored and pursued as acai berry is
being tested for potential inhibition effects on this enzyme looking for potential
DDI. While diosmetin was found to be largely responsible for inhibition of
CYP3A4 in the presence of acai berry fractions, further research must be done to
further explore how acai berry is actually metabolized in vivo and weather
diosmetin is conjugated with other proteins or flavonoids in vivo.
Results from these further studies can help illustrate how relevant acai
berry in to inhibiting CYP 3A4 in a physiological settings. Another component of
further research that must be determined is the amount of diosmetin per gram or
volume of acai berry as it will prove to be relevant in dosage information
regarding how much acai has to be consumed to revive an effective dose of
diosmetin to inhibit CYP 4A4. The goal of this research was to determine if there
was an adverse drug interaction caused by acai berry on CYP 3A4. These
preliminary studies suggest that there is such a negative correlation between
diosmetin and CYP 3A4 potentially leading to verifying that acai berry fractions
and components of acai berry, specifically diosmetin, may inhibit the enzyme
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3A4, thus leading to a toxic build-up of certain substrates of 3A4 mainly which
are pharmaceuticals (9), thus leading to potential toxicity of these drugs while
consuming acai berry. The relevance of this research might be avoiding
consumption of acai berry while taking certain drugs such as statins.
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Future Research

Future research is to be conducted in order to reinforce the finding that diosmetin
is the primary inhibitor of CYP3A4 found in acaí berries. The dose response that this
flavonoid can cause in the bod due to a specific amount of acai berries intake is also to be
determined. Pharmaceutical products consumption along with the acai berries is
dangerous and can cause drug-drug interactions. Furthermore, 94-H fraction is marked as
a potential inhibitor of CYP3A4 isoform (20).
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